Endeavor Launches With $62m And A Hedgehog Inhibitor From Lilly

Co-Founded By Former Impact Biomedicines CEO, Initial Focus Is IPF

 
• By Mandy Jackson
  
Neon Light Sign Lungs Icon
Endeavor's initial focus is IPF but it is looking at additional lung disease programs • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Financing

More from Business